Comparison of prostate cancer survival in Germany and the <scp>USA</scp>: can differences be attributed to differences in stage distributions?

Winter, Alexander; Sirri, Eunice; Jansen, Lina; Wawroschek, Friedhelm; Kieschke, Joachim; Castro, Felipe A.; Krilavičiūtė, Agnė; Holleczek, Bernd; Emrich, Katharina; Waldmann, Annika; Brenner, Hermann

doi:10.1111/bju.13537

Cited by 34 publications

(22 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in the Munich Cancer Registry, the number of men under AS/WW was around 20% in both periods, whereas we observed about 28% in the Canton of Zurich. Evaluating the RS of PCa patients in Germany revealed an overall 10-year RS of 91% [22,23], and studies based on US SEER data observed a 10-year RS of PCa patients between 95 and 100% [23,24]. The RS in our study is comparable with that observed in Germany, but is lower than in the US.…”

Section: Discussionsupporting

confidence: 74%

See 1 more Smart Citation

Primary Treatment Choice Over Time and Relative Survival of Prostate Cancer Patients: Influence of Age, Grade, and Stage

et al. 2017

View full text Add to dashboard Cite

Background: The aim of this study was to assess associations of stage, grade, and age with the primary treatment of prostate cancer (PCa) patients comparing the incidence years 2000/2001 and 2012/2013, and to estimate the relative survival (RS) for patients diagnosed in 2000/2001. Methods: We included 1,541 men diagnosed in 2000/2001 and 1,605 men diagnosed in 2012/2013. Multiple imputation methods were applied to missing data for stage and grade. Multinomial logistic regression analyses were used to explore the associations of stage, grade, and age with treatment. RS was estimated using the Ederer II approach. Results: In 2000/2001, older patients were more likely to choose active surveillance (AS)/watchful waiting (WW) or to receive androgen deprivation therapy (ADT) compared to surgery; in 2012/2013, this association was only observed for ADT but not for AS/WW. In 2000/2001, the overall 1-, 5-, and 10-year RS was approximately 99, 94, and 92%, respectively. RS was highest for patients who underwent surgical procedures or radiotherapy and considerably lower for patients with ADT. Conclusion: Our data show that today AS/WW is an option not only for patients with a life expectancy of < 10 years but also for younger men with localized PCa. PCa patients have a good RS if the cancer is diagnosed at an early stage.

show abstract

Section: Discussionsupporting

confidence: 74%

“…The RS in our study is comparable with that observed in Germany, but is lower than in the US. Different incidence and stage distributions in the US and Germany may partly explain these differences [23]. In the US, PSA screening was used more frequently and introduced earlier compared with Switzerland or Germany.…”

Section: Discussionmentioning

confidence: 99%

Primary Treatment Choice Over Time and Relative Survival of Prostate Cancer Patients: Influence of Age, Grade, and Stage

et al. 2017

View full text Add to dashboard Cite

show abstract

“…We did not compared the difference of MIR improvement between countries according to the expenditures in the health care system. However, previous studies had shown the advantages of survival rate of developed countries such as America and European countries717. It is no doubt that, in recent years, limited improvement of survival rate in prostate cancer was achieved but they still had better MIRs compared with those countries with low expenditures in the health care system which were shown in our results717.…”

Section: Discussionsupporting

confidence: 51%

“…This means that besides the dietary, genetic, and environmental contributions of prostate risk, early screenings and advanced surgical and personalized therapy play important roles in improving clinical outcomes which contribute to low MIR15141516. An observation study found that early detection or a lead time bias of more widespread utilization and earlier introduction of PSA testing in America would cause the differences in incidence and stage distributions over time which would influence the survival7. Early detection and appropriate treatments including the advanced surgical intervention equipment and personalized therapies lead to large expenditures in the health care system.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prostate Cancer Mortality-To-Incidence Ratios Are Associated with Cancer Care Disparities in 35 Countries

Chen

Wang

et al. 2017

Sci Rep

View full text Add to dashboard Cite

The variation in mortality-to-incidence ratios (MIRs) among countries reflects the clinical outcomes and the available interventions for colorectal cancer treatments. The association between MIR of prostate cancer and cancer care disparities among countries is an interesting issue that is rarely investigated. For the present study, cancer incidence and mortality rates were obtained from the GLOBOCAN 2012 database. The rankings and total expenditures on health of various countries were obtained from the World Health Organization (WHO). The association between variables was analyzed by linear regression analyses. In this study, we estimated the role of MIRs from 35 countries that had a prostate cancer incidence greater than 5,000 cases per year. As expected, high prostate cancer incidence and mortality rates were observed in more developed regions, such as Europe and the Americas. However, the MIRs were 2.5 times higher in the less developed regions. Regarding the association between MIR and cancer care disparities, countries with good WHO ranking and high total expenditures on health/gross domestic product (GDP) were significant correlated with low MIR. The MIR variation for prostate cancer correlates with cancer care disparities among countries further support the role of cancer care disparities in clinical outcome.

show abstract

Trajectories of quality of life, life satisfaction, and psychological adjustment after prostate cancer

et al. 2017

View full text Add to dashboard Cite

BackgroundTo describe trajectories of health‐related quality of life (QoL), life satisfaction, and psychological adjustment for men with prostate cancer over the medium to long term and identify predictors of poorer outcomes using growth mixture models.MethodsOne‐thousand sixty‐four (82.4% response) men diagnosed with prostate cancer were recruited close to diagnosis and assessed over a 72‐month (6‐year) period with self‐report assessment of health‐related QoL, life satisfaction, cancer‐related distress, and prostate specific antigen anxiety. Urinary, bowel, and sexual function were also assessed using validated questionnaires.ResultsPoorer physical QOL was predicted by older age, lower education, lower income, comorbidities, and receiving hormone therapy. Lower life satisfaction was related to younger age, lower income, not being partnered, and comorbidities. Poorer psychological trajectories were predicted by younger age, lower income, comorbidities, and receiving radical prostatectomy or brachytherapy. Better urinary, bowel, and sexual function were related to better global outcomes over time. Anxiety about prostate specific antigen testing was rare.ConclusionsDistinct trajectories exist for medium‐ to long‐term QoL, life satisfaction, and psychological adjustment after prostate cancer; with age and socioeconomic deprivation playing a differential role in men's survivorship profile and the impact of functional status on outcomes increasing over time. These results reinforce the need for an appraisal of men's life course in addition to treatment side effects when planning survivorship care after cancer.

show abstract

Comparison of prostate cancer survival in Germany and the USA: can differences be attributed to differences in stage distributions?

Cited by 34 publications

References 32 publications

Primary Treatment Choice Over Time and Relative Survival of Prostate Cancer Patients: Influence of Age, Grade, and Stage

Primary Treatment Choice Over Time and Relative Survival of Prostate Cancer Patients: Influence of Age, Grade, and Stage

Prostate Cancer Mortality-To-Incidence Ratios Are Associated with Cancer Care Disparities in 35 Countries

Trajectories of quality of life, life satisfaction, and psychological adjustment after prostate cancer

Contact Info

Product

Resources

About